Is there a single diagnostic biomarker for ME/CFS?

No. ME/CFS remains a clinical diagnosis. Multiple biomarker domains show group-level differences vs healthy controls but none are FDA-validated as standalone diagnostic tests.

What biomarkers are most replicated in ME/CFS research?

Meta-analyses report altered cytokines (IL-1, TGF-β), elevated acylcarnitines, reduced heart rate variability, mitochondrial abnormalities, and urinary metabolite signatures.

Peer-Reviewed Literature Synthesis

ME/CFS Biomarker Atlas

Molecular, metabolic, immunological, and autonomic alterations in myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) compared to healthy sedentary and active controls — including post-exertional malaise (PEM) phenotypes.

Literature Overview

Synthesized from systematic reviews and meta-analyses through 2024. ME/CFS lacks a validated single biomarker; multi-system dysfunction across immune signaling, mitochondrial metabolism, and autonomic regulation is the dominant research paradigm.

Studies in cytokine review

Urinary biomarker studies

Acylcarnitine studies

HRV studies meta-analyzed

Immune & Inflammatory Signaling

Low-grade immune activation with inconsistent cytokine directions across studies. Meta-analyses identify IL-1 and TGF-β as most consistently elevated; TNF-α and IL-6 show heterogeneous results.

RNase L pathway dysregulation
NK cell cytotoxicity reduction
CD8+ T cell functional impairment

Mitochondrial & Metabolic Dysfunction

Impaired oxidative phosphorylation, elevated acylcarnitines, and reduced ATP production — consistent with cellular energy deficit underlying PEM and exercise intolerance.

Elevated C16 & C18 acylcarnitines
Reduced ATP resynthesis post-exercise
Altered amino acid metabolism

Autonomic & Neuroimmune Dysregulation

Reduced heart rate variability, orthostatic intolerance, and GPCR autoantibodies overlap with dysautonomia phenotypes seen in Long COVID and PACVS.

Reduced HRV (time & frequency domain)
β-adrenergic & muscarinic autoantibodies
Altered cortisol rhythm

Searchable Alterations Database

Filter by category. HC = healthy controls; PEM = post-exertional malaise challenge. Markers tagged "LC overlap" are also reported in long COVID with ME/CFS phenotype.

Overlap with Long COVID & PACVS

ME/CFS criteria are met by a substantial subset of long COVID patients. Metabolic (serine, sarcosine, ceramides), autonomic (HRV, POTS), and GPCR autoantibody findings are shared across conditions. See the Long COVID Biomarker Atlas and PACVS Biomarker Atlas for infection- and vaccination-specific markers.

PEM timing matters

Many metabolic and immune biomarkers are measured at baseline in ME/CFS cohorts, but PEM — the hallmark symptom — may only be captured after standardized exertion challenge (e.g., 2-day CPET). Acylcarnitine elevations and lactate abnormalities may be more pronounced post-exercise than at rest (Holden et al., 2020; Jinushi et al., 2023).

Linked clinical trials Commercially orderable Also consumable product

Marker / Metabolite	Direction	Category	vs. Comparison	Associated Symptoms	Key Reference

Category Deep Dives

🔥 Cytokines & Inflammatory Mediators

IL-1 (IL-1α/β)↑ meta-analysis
TGF-β↑ meta-analysis
TNF-α↕ heterogeneous
IL-6↕ heterogeneous
IL-8 / CXCL8↕ variable
CRP↕ low-grade
Leptin↑ inflammatory proteins

⚡ Mitochondrial & Energy Metabolism

Acylcarnitines (C16, C18)↑ meta-analysis
ATP production capacity↓ PEM
Lactate (rest & exercise)↑
Pyruvate dehydrogenase activity↓
Mitochondrial membrane potential↓
2-day CPET VO₂ decline↓ day 2

🛡️ Immune Cell Function

NK cell cytotoxicity↓
CD8+ T cell perforin↓
RNase L (37-kDa fragment)↑ dysregulated
Neutrophil elastase↑
CD26 / sCD26 (DPPIV)↕ altered

💓 Autonomic & Cardiovascular

Heart rate variability (RMSSD)↓ meta-analysis
LF/HF ratio↕ altered
Orthostatic HR increment↑ POTS
Blood pressure variability↑
Baroreflex sensitivity↓

🧠 Neurological & Autoimmune

β2-adrenergic receptor autoantibodies↑
Muscarinic cholinergic autoantibodies↑
Neurofilament light chain (NfL)↕ subset
Cortisol (flattened diurnal)↕ HPA axis

🧪 Urinary & Metabolomic Signatures

Urinary metabolite panelDiscriminant
Creatinine-normalized metabolitesAltered
Serine / sarcosine (plasma)↓ LC overlap
Kynurenine pathway↑
Tryptophan / benzoate metabolites↕ BioMapAI 2025
Branched-chain amino acids (BCAAs)↕ BioMapAI 2025
Bile acids (plasma)↕ BioMapAI 2025

🔬 Multi-Omics & Immune Profiling

MAIT cell activation (IFN-γ / GzA)↑ BioMapAI 2025
γδT cell frequency / activation↑ BioMapAI 2025
Short-chain fatty acids (gut)↕ microbiome axis
PBMC electrical impedance↑ nanoneedle 100%
PBMC Raman spectroscopic fingerprintDiscriminant 91%

🧬 Genomic / Epigenetic

EpiSwitch 200-CC panelDiagnostic 96% acc.
Circulating miRNA (11-panel)Discriminant classifier
IL-2 / JAK-STAT pathway CCs↕ EpiSwitch 2025
TLR signalling CCs↕ EpiSwitch 2025

Key References

Systematic Review

Biomarkers for diagnosing ME/CFS: a systematic review

Maksoud R et al. BMC Med. 2023;21:232

DOI: 10.1186/s12916-023-02893-9 →

Systematic Review — Cytokines

A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID)

Corbitt M et al. BMC Neurol. 2019;19:207

DOI: 10.1186/s12883-019-1433-0 →

Meta-Analysis — Inflammatory Proteins

Inflammatory proteins are altered in chronic fatigue syndrome — a systematic review and meta-analysis

Strawbridge R et al. Neurosci Biobehav Rev. 2019;107:69–83

DOI: 10.1016/j.neubiorev.2019.08.011 →

Meta-Analysis — Acylcarnitines

Comparison of serum acylcarnitine levels in patients with ME/CFS and healthy controls: a systematic review and meta-analysis

Jinushi R et al. J Transl Med. 2023;21:398 — Lower serum acylcarnitine in ME/CFS

DOI: 10.1186/s12967-023-04226-z →

Meta-Analysis — HRV

Evidence of altered cardiac autonomic regulation in ME/CFS: a systematic review and meta-analysis

Nelson MJ et al. Medicine (Baltimore). 2019;98(43):e17600

DOI: 10.1097/MD.0000000000017600 →

Meta-Analysis — 2-Day CPET

The Prospects of the Two-Day Cardiopulmonary Exercise Test (CPET) in ME/CFS Patients: A Meta-Analysis

Lim EJ et al. J Clin Med. 2020;9(12):4040 — Day-2 decline in VO₂ peak and workload at ventilatory threshold

DOI: 10.3390/jcm9124040 →

Meta-Analysis — Urinary

A systematic review and meta-analysis of urinary biomarkers in ME/CFS

Taccori A et al. J Transl Med. 2023;21:440

DOI: 10.1186/s12967-023-04295-0 →

Systematic Review — Mitochondria

A systematic review of mitochondrial abnormalities in ME/CFS/SEID

Holden S et al. J Transl Med. 2020;18:290

DOI: 10.1186/s12967-020-02452-3 →

Primary Study — Long COVID overlap

Metabolomic and Immune Alterations in Long COVID Patients with ME/CFS

Saito S et al. Front Immunol. 2024;15:1341843

DOI: 10.3389/fimmu.2024.1341843 →

Multi-Omics ML — BioMapAI

AI-driven multi-omics modeling of ME/CFS (BioMapAI)

Xiong R, Oh J, Unutmaz D et al. Nat Med. 2025 (Jackson Laboratory)

DOI: 10.1038/s41591-025-03788-3 →

Diagnostic Platform — Nanoneedle

A nanoelectronics-blood-based diagnostic biomarker for ME/CFS

Esfandyarpour R et al. PNAS. 2019;116(21):10250–10257 (Ron Davis lab, Stanford)

DOI: 10.1073/pnas.1901274116 →

Genomic — Circulating miRNA

Circulating microRNA expression signatures accurately discriminate myalgic encephalomyelitis from fibromyalgia and comorbid conditions

Nepotchatykh E et al. Sci Rep. 2023;13:1896 (Moreau lab, Montréal)

DOI: 10.1038/s41598-023-28955-9 →

Genomic — EpiSwitch

Development and validation of blood-based diagnostic biomarkers for ME/CFS using EpiSwitch 3D genomic profiling (EPI-ME)

Hunter E, …, Pchejetski D. J Transl Med. 2025;23:1048 (Oxford BioDynamics / UEA). Sensitivity 92%, Specificity 98%

DOI: 10.1186/s12967-025-07203-w →

Diagnostic Platform — Raman Spectroscopy

Raman spectroscopic fingerprint of PBMCs for ME/CFS diagnosis

Morten K et al. University of Oxford. 2023. Accuracy ~91% (ME/CFS vs HC); severity classification 84%

ME Association →

Disclaimer: Educational synthesis only — not medical advice. ME/CFS biomarker findings vary by diagnostic criteria (Fukuda, Canadian, IOM/SEID, ICC), illness duration, and comparison group. No biomarker is validated as a standalone diagnostic test. Consult qualified healthcare providers for clinical interpretation.